TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 34353223

Group type: EXPERIMENTAL
Intervention: Premenopausal women with menstruation related asthma worsening (PMA)
Number of subjects: 622

Group type: EXPERIMENTAL
Intervention: Women with irregular menstruation
Number of subjects: 622

Group type: EXPERIMENTAL
Intervention: Peri/postmenopausal women with menopausal hormone therapy (MHT)
Number of subjects: 622

Group type: COMPARATOR
Intervention: Women without PMA
Number of subjects: 622

Group type: COMPARATOR
Intervention: Women without MHT
Number of subjects: 622
Study: 35148213

Group type: EXPERIMENTAL
Intervention: Inverted small flap (SF < 2 disc diameters)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Inverted large flap (LF from 2 to 4 disc diameters)
Number of subjects: 25
Study: 34101308

Group type: EXPERIMENTAL
Intervention: Sacubitril/valsartan
Number of subjects: 8398

Group type: COMPARATOR
Intervention: Enalapril
Number of subjects: 8398
Study: 32600149

Group type: EXPERIMENTAL
Intervention: Operative treatment
Number of subjects: 64

Group type: COMPARATOR
Intervention: Nonoperative treatment
Number of subjects: 64
Study: 35505432

Group type: EXPERIMENTAL
Intervention: Midazolam followed by dexmedetomidine (group M-D)
Number of subjects: 252

Group type: EXPERIMENTAL
Intervention: Midazolam followed by propofol (group M-P)
Number of subjects: 252

Group type: COMPARATOR
Intervention: Midazolam alone (group M)
Number of subjects: 252
Study: 33503496

Group type: EXPERIMENTAL
Intervention: 6-month physical activity intervention (Exercise Group)
Number of subjects: 250

Group type: COMPARATOR
Intervention: Health & Wellness Group (attention-comparison condition)
Number of subjects: 250
Study: 35080109

Group type: EXPERIMENTAL
Intervention: 0.125 mg/kg IV pimobendan
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: 0.25 mg/kg IV pimobendan
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: IV pimobendan (both doses)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: IV pimobendan
Number of subjects: 6
Study: 32390550

Group type: EXPERIMENTAL
Intervention: Endovascular treatment in patients with prior OAC
Number of subjects: 3162

Group type: COMPARATOR
Intervention: Endovascular treatment in patients without prior OAC
Number of subjects: 3162
Study: 33175117

Group type: EXPERIMENTAL
Intervention: Low-pressure BFR and resistance training (LP-RT)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: High-pressure BFR and resistance training (HP-RT)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Resistance training (RT)
Number of subjects: 24
Study: 35588354

Group type: EXPERIMENTAL
Intervention: Active scapular correction
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 28
Study: 33417146

Group type: EXPERIMENTAL
Intervention: Mirabegron 50 mg once daily for 4 weeks (Group A; n = 32)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Placebo for 4 weeks (Group B; n = 34)
Number of subjects: 66
Study: 32730852

Group type: EXPERIMENTAL
Intervention: Prespecified statistical analysis approach available
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Prespecified statistical analysis approach discrepancies
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Statistician blinding until SAP signed off
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Statistician blinding until database locked
Number of subjects: 100
Study: 36404386

Group type: EXPERIMENTAL
Intervention: Sacubitril-valsartan
Number of subjects: 8399

Group type: COMPARATOR
Intervention: Enalapril
Number of subjects: 8399
Study: 32075818

Group type: EXPERIMENTAL
Intervention: Pressure-measuring contact lens (PMCL) device
Number of subjects: 8

Group type: COMPARATOR
Intervention: Dynamic contour tonometry (DCT)
Number of subjects: 8
Study: 33751206

Group type: EXPERIMENTAL
Intervention: Patient Decision Aids (PDAs)
Number of subjects: 3
Study: 33026938

Group type: EXPERIMENTAL
Intervention: Pembrolizumab 200 mg every 3 weeks for up to 2 years
Number of subjects: 628

Group type: COMPARATOR
Intervention: Chemotherapy (investigator's choice of paclitaxel, docetaxel, or irinotecan)
Number of subjects: 628

Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Number of subjects: 628

Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 628
Study: 33621314

Group type: EXPERIMENTAL
Intervention: Hyrax expander
Number of subjects: 39

Group type: COMPARATOR
Intervention: Haas expander
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Both expanders
Number of subjects: 39
Study: 32584893

Group type: EXPERIMENTAL
Intervention: Digital device providing real-time visualized brushing instructions
Number of subjects: 112

Group type: COMPARATOR
Intervention: Control group using a digital device that only collected brushing logs
Number of subjects: 112
Study: 35597518

Group type: EXPERIMENTAL
Intervention: Cerebellar anodal tDCS
Number of subjects: 20

Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 20
Study: 34776157

Group type: EXPERIMENTAL
Intervention: Specific cervical manipulation at the C6-7 segment (SCM)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Non-specific cervical manipulation (NSCM)
Number of subjects: 21
Study: 35393715

Group type: EXPERIMENTAL
Intervention: Integrated intervention combining cognitive-behavioural stress management (CBSM) and progressive muscle relaxation (PMRs)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 30
Study: 32662699

Group type: EXPERIMENTAL
Intervention: Internet intervention with brief email guidance from a health educator (at least four structured emails during the first two weeks)
Number of subjects: 238

Group type: COMPARATOR
Intervention: Internet intervention without brief email guidance
Number of subjects: 238
Study: 36473425

Group type: EXPERIMENTAL
Intervention: ARA 100 mg/kg and DHA 50 mg/kg
Number of subjects: 120

Group type: COMPARATOR
Intervention: Medium chain triglycerides (MCT) oil
Number of subjects: 120
Study: 33241958

Group type: EXPERIMENTAL
Intervention: STHT (3-week strength-oriented training followed by 5-week hypertrophy-oriented training)
Number of subjects: 26

Group type: COMPARATOR
Intervention: HT (8-week hypertrophy-oriented training)
Number of subjects: 26
Study: 32785940

Group type: EXPERIMENTAL
Intervention: Immunotherapy (single agents and combinations)
Number of subjects: 153

Group type: COMPARATOR
Intervention: Monotherapy
Number of subjects: 153

Group type: COMPARATOR
Intervention: Combination therapy
Number of subjects: 153
Study: 36145087

Group type: EXPERIMENTAL
Intervention: Wagyu‐Cross beef (120 g consumed four days/week for four weeks)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Commercial beef (120 g consumed four days/week for four weeks)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Wagyu‐Cross beef
Number of subjects: 0

Group type: COMPARATOR
Intervention: Commercial beef
Number of subjects: 0
Study: 35429946

Group type: EXPERIMENTAL
Intervention: Caffeine (20 mg/kg initial dose, then 10 mg/kg daily maintenance)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Caffeine
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control
Number of subjects: 90
Study: 33165219

Group type: EXPERIMENTAL
Intervention: Mindfulness intervention (6 × 20-minute sessions of focused-attention mindfulness)
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Sham mindfulness intervention
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Mindfulness intervention
Number of subjects: 93

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 93
Study: 35183551

Group type: EXPERIMENTAL
Intervention: AI-assisted group (n = 295)
Number of subjects: 576

Group type: COMPARATOR
Intervention: Unaided group (n = 281)
Number of subjects: 576

Group type: EXPERIMENTAL
Intervention: Nondermatology trainees (AI-assisted, n = 150)
Number of subjects: 576

Group type: EXPERIMENTAL
Intervention: Dermatology residents (AI-assisted)
Number of subjects: 576

Group type: EXPERIMENTAL
Intervention: AI-assisted group (trainees)
Number of subjects: 576
Study: 34814657

Group type: EXPERIMENTAL
Intervention: Mud plus bath therapy (group 1)
Number of subjects: 89
Study: 32891286

Group type: EXPERIMENTAL
Intervention: Cupping therapy at -0.02 mpa
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Cupping therapy at -0.03 mpa
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Cupping therapy at -0.05 mpa
Number of subjects: 91
Study: 32161005

Group type: EXPERIMENTAL
Intervention: Anti-VEGF therapy
Number of subjects: 54
Study: 35124808

Group type: EXPERIMENTAL
Intervention: Preoperative high-dose dexamethasone (1 mg/kg)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 120
Study: 34330595

Group type: EXPERIMENTAL
Intervention: Aspirin 300 mg once daily
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 35523502

Group type: EXPERIMENTAL
Intervention: Low-dose CT scan (LDCT)
Number of subjects: 495

Group type: EXPERIMENTAL
Intervention: Lung ultrasonography (LUS)
Number of subjects: 495

Group type: COMPARATOR
Intervention: Chest X-ray (CXR)
Number of subjects: 495
Study: 34852814

Group type: EXPERIMENTAL
Intervention: Educational program based on Theory of Planned Behavior (TPB)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 150
Study: 34934009

Group type: EXPERIMENTAL
Intervention: CPAP + pressure support ventilation (PSV)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Pressure control (PC)/intermittent mandatory ventilation (IMV) + PSV
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Downward titration of the level of pressure support (PSV)
Number of subjects: 35
Study: 32088668

Group type: EXPERIMENTAL
Intervention: Live harp music
Number of subjects: 46

Group type: COMPARATOR
Intervention: Recorded harp music
Number of subjects: 46
Study: 34197338

Group type: EXPERIMENTAL
Intervention: Dog-Assisted Therapy (DAT)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control group (no DAT)
Number of subjects: 21
Study: 33469944

Group type: EXPERIMENTAL
Intervention: Moderate increasing trajectory from age 10 to 18
Number of subjects: 704

Group type: EXPERIMENTAL
Intervention: Low-to-moderate increasing trajectory across childhood
Number of subjects: 704

Group type: COMPARATOR
Intervention: Very low decreasing group (baseline)
Number of subjects: 704
Study: 32100168

Group type: EXPERIMENTAL
Intervention: Spiritual care based on the sound heart model
Number of subjects: 92

Group type: COMPARATOR
Intervention: Routine nursing interventions (Control)
Number of subjects: 92
Study: 36456715

Group type: EXPERIMENTAL
Intervention: Lespedeza cuneata extract gargle
Number of subjects: 82

Group type: COMPARATOR
Intervention: Saline gargle
Number of subjects: 82
Study: 34298029

Group type: EXPERIMENTAL
Intervention: Minocycline 200 mg with Oxycodone 40 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Minocycline 100 mg with Oxycodone 40 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Oxycodone 40 mg alone
Number of subjects: 12
Study: 33306927

Group type: EXPERIMENTAL
Intervention: Motion-control shoes
Number of subjects: 372

Group type: COMPARATOR
Intervention: Standard neutral shoes
Number of subjects: 372
Study: 32696964

Group type: EXPERIMENTAL
Intervention: Strong with Sam (SmS) program
Number of subjects: 92

Group type: COMPARATOR
Intervention: Wait list control group
Number of subjects: 92
Study: 33743615

Group type: EXPERIMENTAL
Intervention: T1-2WI radiomic model using multivariable logistic regression (MLR)
Number of subjects: 252

Group type: COMPARATOR
Intervention: Clinical model
Number of subjects: 252
Study: 32474633

Group type: EXPERIMENTAL
Intervention: Deep learning algorithm based on 3D ResNet architecture
Number of subjects: 694
Study: 35129789

Group type: EXPERIMENTAL
Intervention: Medication reconciliation and medication review conducted by study pharmacists in addition to standard care
Number of subjects: 402

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 402
Study: 32950693

Group type: EXPERIMENTAL
Intervention: Defibrotide (6.25 mg/kg every 6 hours, administered as a 2-hour i.v. infusion, for a minimum of 21 days or until resolution of VOD/SOS signs and symptoms)
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Defibrotide (25 mg/kg/day in phase 2 study)
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Defibrotide (in T-IND)
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Defibrotide (in pooled phase 2 and 3 studies)
Number of subjects: 1000
Study: 36197920

Group type: EXPERIMENTAL
Intervention: modified directly observed therapy (mDOT)
Number of subjects: 147

Group type: COMPARATOR
Intervention: standard individual therapy (SIT)
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: groups therapy (GT)
Number of subjects: 147
Study: 34011310

Group type: EXPERIMENTAL
Intervention: Venlafaxine
Number of subjects: 184

Group type: COMPARATOR
Intervention: Fluoxetine
Number of subjects: 184
Study: 34611892

Group type: EXPERIMENTAL
Intervention: Intensified therapy with aspirin 100 mg once daily in combination with clopidogrel 150 mg once daily
Number of subjects: 434

Group type: EXPERIMENTAL
Intervention: Intensified therapy with aspirin 100 mg once daily in combination with clopidogrel 75 mg once daily plus cilostazol 100 mg twice daily
Number of subjects: 434

Group type: EXPERIMENTAL
Intervention: Intensified therapy with aspirin 100 mg once daily in combination with ticagrelor 90 mg twice daily
Number of subjects: 434

Group type: COMPARATOR
Intervention: Standard therapy with clopidogrel 75 mg once daily (STD)
Number of subjects: 434

Group type: EXPERIMENTAL
Intervention: Intensified therapy (all combinations)
Number of subjects: 434
Study: 34245031

Group type: EXPERIMENTAL
Intervention: Generalized estimating equation (GEE) approach for sample size determination
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional method for sample size determination
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Proposed GEE sample size method
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Team-based approach
Number of subjects: 0
Study: 32129263

Group type: EXPERIMENTAL
Intervention: 20% mannitol
Number of subjects: 30

Group type: COMPARATOR
Intervention: 3% hypertonic saline (HTS)
Number of subjects: 30
Study: 35588336

Group type: EXPERIMENTAL
Intervention: Laparoscopic ventral mesh rectopexy (LVMR)
Number of subjects: 28
Study: 33849821

Group type: EXPERIMENTAL
Intervention: Ziyin recipe
Number of subjects: 0

Group type: COMPARATOR
Intervention: Western medicine (CC and HMG)
Number of subjects: 0
Study: 36417652

Group type: EXPERIMENTAL
Intervention: Kinesio taping combined with a 4-week neck exercise program (n=29)
Number of subjects: 60
Study: 32212856

Group type: EXPERIMENTAL
Intervention: Vortioxetine with cognitive training
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo with cognitive training
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Both groups (Vortioxetine and Placebo)
Number of subjects: 100
Study: 36470716

Group type: EXPERIMENTAL
Intervention: 3D printing models (3Dp)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (without 3Dp models)
Number of subjects: 100
Study: 34299775

Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT) - 10 × 1-min cycling at VO2peak power output
Number of subjects: 25
Study: 34644389

Group type: EXPERIMENTAL
Intervention: iCanQuit
Number of subjects: 169

Group type: COMPARATOR
Intervention: QuitGuide
Number of subjects: 169
Study: 32138563

Group type: EXPERIMENTAL
Intervention: β-Alanine (BA) supplementation (12 g·day‐1 for 14 days)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 19
Study: 35377934

Group type: EXPERIMENTAL
Intervention: PDL injection and alternative palatal infiltration
Number of subjects: 133

Group type: COMPARATOR
Intervention: Mock PDL injection and conventional palatal infiltration
Number of subjects: 133
Study: 33982892

Group type: EXPERIMENTAL
Intervention: Genetically determined fasting insulin concentrations
Number of subjects: 360453

Group type: EXPERIMENTAL
Intervention: Outlier-corrected fasting insulin concentrations
Number of subjects: 360453

Group type: EXPERIMENTAL
Intervention: Multivariable MR analyses adjusted for BMI
Number of subjects: 360453

Group type: EXPERIMENTAL
Intervention: Polygenic scores for fasting insulin
Number of subjects: 360453

Group type: EXPERIMENTAL
Intervention: Gout risk
Number of subjects: 360453
Study: 33051075

Group type: EXPERIMENTAL
Intervention: Reamer-Irrigator-Aspirator (RIA) at a diameter of 4.0 mm larger than isthmus
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Reamer-Irrigator-Aspirator (RIA) at a diameter of 2.5 mm larger than isthmus
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Reamer-Irrigator-Aspirator (RIA) at a diameter of 1.5 mm larger than isthmus
Number of subjects: 45

Group type: COMPARATOR
Intervention: Contralateral femur left intact without reaming
Number of subjects: 45
Study: 35199478

Group type: EXPERIMENTAL
Intervention: Co-administration of esaxerenone and SGLT2 inhibitor
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Esaxerenone
Number of subjects: 0

Group type: COMPARATOR
Intervention: SGLT2 inhibitor
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 34221093

Group type: EXPERIMENTAL
Intervention: Rhythmic Breathing (RB) performed every 12 hours for three consecutive days after surgery
Number of subjects: 60

Group type: COMPARATOR
Intervention: Routine care (opioid analgesics) with no additional interventions
Number of subjects: 60
Study: 35124234

Group type: EXPERIMENTAL
Intervention: Apixaban
Number of subjects: 574

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 574
Study: 35259416

Group type: EXPERIMENTAL
Intervention: Prophylactic cranial irradiation (PCI)
Number of subjects: 670

Group type: COMPARATOR
Intervention: No prophylactic cranial irradiation (no PCI)
Number of subjects: 670

Group type: EXPERIMENTAL
Intervention: Prophylactic cranial irradiation (PCI) with durvalumab
Number of subjects: 670

Group type: EXPERIMENTAL
Intervention: Prophylactic cranial irradiation (PCI) with fewer fractions
Number of subjects: 670

Group type: EXPERIMENTAL
Intervention: Prophylactic cranial irradiation (PCI) excluding indirect costs
Number of subjects: 670
Study: 32438041

Group type: EXPERIMENTAL
Intervention: Self-sampling arm (vaginal self-sampling kit)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Control arm (encouraged to make an appointment for Pap smear)
Number of subjects: 88
Study: 34312190

Group type: EXPERIMENTAL
Intervention: DHEA supplementation (sublingual or oral) at 50, 100 or 200 mg daily over 3 days
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: DHEA supplementation
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: DHEA supplementation (oral vs sublingual)
Number of subjects: 270
Study: 32495381

Group type: EXPERIMENTAL
Intervention: 3MDR (multi-modular motion-assisted memory desensitization and reprocessing)
Number of subjects: 42
Study: 34426064

Group type: EXPERIMENTAL
Intervention: Monthly group‐based diabetes self‐management education (DSME) and monthly vouchers ($28‐$140/month) redeemable for fruits and vegetables at local markets
Number of subjects: 97
Study: 32987647

Group type: EXPERIMENTAL
Intervention: Colostrum (2 × 500 mg) harvested at 2 hours after delivery
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Colostrum (2 × 500 mg) harvested at 24 hours after delivery
Number of subjects: 31

Group type: COMPARATOR
Intervention: Colostrum (2 × 500 mg) harvested at 72 hours after delivery
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo (whey)
Number of subjects: 31
Study: 34287475

Group type: EXPERIMENTAL
Intervention: Dengzhan Shengmai capsule 0.36 g three times a day
Number of subjects: 294

Group type: COMPARATOR
Intervention: Donepezil hydrochloride 5 mg once a day
Number of subjects: 294
Study: 34601649

Group type: EXPERIMENTAL
Intervention: Quadriceps tendon graft with bone block (BT)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Bone-patellar tendon-bone graft (BTB)
Number of subjects: 40
Study: 34596269

Group type: EXPERIMENTAL
Intervention: Low-dose intramuscular testosterone treatment (1 mg/kg/month)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Per oral letrozole treatment (2.5 mg/day)
Number of subjects: 28
Study: 33064410

Group type: EXPERIMENTAL
Intervention: Stress measured via salivary cortisol and testosterone
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Pupillometry measuring left eye pupil constriction
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Pupil constriction latency
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Testosterone and pupil constriction latency
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Hormones with left eye pupil constriction difference
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Testosterone-to-cortisol ratio decline with left eye pupil constriction
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Testosterone-to-cortisol ratio decline and somatosensory processing
Number of subjects: 25
Study: 35999317

Group type: EXPERIMENTAL
Intervention: Intracorporeal anastomosis (IIA)
Number of subjects: 140
Study: 32915354

Group type: EXPERIMENTAL
Intervention: RECALL (Reading to Engage Children with Autism in Language and Learning)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 31
Study: 32933509

Group type: EXPERIMENTAL
Intervention: Trial of labor after cesarean (TOLAC)
Number of subjects: 708

Group type: EXPERIMENTAL
Intervention: Predictive model for VBAC success
Number of subjects: 708

Group type: EXPERIMENTAL
Intervention: Decision curve analysis of the predictive model
Number of subjects: 708
Study: 34666139

Group type: EXPERIMENTAL
Intervention: Cryoballoon ablation (CBA)
Number of subjects: 203

Group type: COMPARATOR
Intervention: Antiarrhythmic drug (AAD) therapy
Number of subjects: 203
Study: 33015912

Group type: EXPERIMENTAL
Intervention: 1-day low-residue diet (LRD) with standard laxative treatment
Number of subjects: 855

Group type: COMPARATOR
Intervention: 3-day low-residue diet (LRD) with standard laxative treatment
Number of subjects: 855

Group type: EXPERIMENTAL
Intervention: 1-day low-residue diet (LRD)
Number of subjects: 855

Group type: COMPARATOR
Intervention: 3-day low-residue diet (LRD)
Number of subjects: 855
Study: 34655400

Group type: EXPERIMENTAL
Intervention: Oral magnesium L‐threonate (MLT) for 12 weeks
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: High‐dose intravenous (IV) magnesium sulfate (MgSO4) for 3 days followed by open‐label MLT for 24 weeks
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: In vitro magnesium supplementation experiments in cells from 14 XMEN patients
Number of subjects: 4
Study: 34865624

Group type: EXPERIMENTAL
Intervention: Hybrid clinical trial procedures using a mobile app for symptom recording and home-collected nasal swabs.
Number of subjects: 99